Press release
Primary Ciliary Dyskinesia Market in the 7MM Projected for Significant Expansion from USD 101 Million| DelveInsight
Primary Ciliary Dyskinesia Market Research DelveInsight
DelveInsight's latest "Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the market size for Primary Ciliary Dyskinesia (PCD) in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase from approximately USD 101 million in 2023 over the next 10 years. Among the 7MM, the US market is expected to rise at a significant CAGR from approximately USD 36 million in 2023. This growth is attributed to increased awareness, improved screening and diagnosis rates, a rising prevalence of the disease, and the anticipated introduction of emerging therapies.
Download the Primary Ciliary Dyskinesia Market report to understand which factors are driving the primary ciliary dyskinesia therapeutic market @ Primary Ciliary Dyskinesia Market Trends [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report also offers an in-depth epidemiological analysis and forecasts up to 2034, segmented by Primary Ciliary Dyskinesia prevalent cases, Primary Ciliary Dyskinesia diagnosed prevalent cases, age-specific cases, Primary Ciliary Dyskinesia prevalence by pathogenic variants in genes, and Primary Ciliary Dyskinesia prevalent cases by clinical manifestations across the 7MM. According to research conducted by DelveInsight's analysts, the general prevalence of PCD is reported to be between 1 in 11,000 and 1 in 16,000 live births, although the actual prevalence may be higher. In the UK, the prevalence is estimated to be 1 in 7,500, with about 3,000 diagnosed prevalent cases. The US, on the other hand, has nearly 1,800 diagnosed prevalent cases in 2023 out of ~70,000 total diagnosed prevalent cases of PCD in 7MM. It has also been observed that children aged 6 to 20 years account for the highest number of cases, particularly in the United States, and this trend is expected to continue during the forecast period.
Discover evolving trends in the primary ciliary dyskinesia patient pool forecasts @ Primary Ciliary Dyskinesia Epidemiology Analysis [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
DelveInsight's analysis reveals that a decent number of companies are launching clinical trials to investigate new treatment options or improve existing ones. The clinical development pipeline includes drugs such as P-1037 IS/VX-371 (PARION SCIENCES), RCT1100 (RECODE THERAPEUTICS), ETH 42 (ETHRIS GmbH), CIL-05 (CILA THERAPEUTICS), among others.
As there is currently no standard treatment for PCD, the focus remains on managing respiratory symptoms, preventing infections, opening airways, and reducing inflammation through antibiotics, bronchodilators, or anti-inflammatory medications. This emphasises the potential of emerging diagnoses and therapies to revolutionise the treatment landscape for PCD.
Among the anticipated emerging therapies, RCT1100 by ReCode Therapeutics, an inhaled mRNA-based investigational therapy, shows promising results in restoring ciliary function in the lungs, addressing the root cause of PCD rather than merely controlling symptoms. The report provides a detailed analysis of the anticipated uptake rates for the potential PCD drugs expected to launch between 2025 and 2034.
Recent developments, including the US FDA's Orphan Drug Designation (ODD) for RCT1100 by ReCode Therapeutics in June 2024, along with significant clinical trial updates for TH 42 (ETHRIS GmbH) and CIL-05 (CILA THERAPEUTICS), emphasise the momentum in the field.
Unlock which primary ciliary dyskinesia emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Primary Ciliary Dyskinesia Drug Insights [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Although PCD presents significant challenges due to its frequent misidentification as a more common respiratory disorder, potentially leading to an underreporting of its true prevalence and significant delays in treatment, the emergence of improved diagnostic methods and novel therapies is set to broaden treatment options and spur market growth.
Table of Contents
1.
KEY INSIGHTS
2.
REPORT INTRODUCTION
3.
PRIMARY CILIARY DYSKINESIA (PCD) MARKET OVERVIEW AT A GLANCE
4.
METHODOLOGY
5.
EXECUTIVE SUMMARY
6.
KEY EVENTS
7.
DISEASE BACKGROUND AND OVERVIEW
8.
PRIMARY CILIARY DYSKINESIA EPIDEMIOLOGY AND PATIENT POPULATION
9.
PRIMARY CILIARY DYSKINESIA PATIENT JOURNEY
10.
PRIMARY CILIARY DYSKINESIA EMERGING THERAPIES
11.
PRIMARY CILIARY DYSKINESIA MARKETED THERAPIES
12.
KOL VIEWS
13.
SWOT ANALYSIS
14.
PRIMARY CILIARY DYSKINESIA UNMET NEEDS
15.
MARKET ACCESS AND REIMBURSEMENT
16.
APPENDIX
17.
DELVEINSIGHT CAPABILITIES
18.
DISCLAIMER
Related Reports:
Primary Ciliary Dyskinesia (PCD) Pipeline Insight [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Primary Ciliary Dyskinesia (PCD) Pipeline Insight report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the PCD companies, including PARION SCIENCES, RECODE THERAPEUTICS, ETHRIS, and CILA THERAPEUTICS.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-ciliary-dyskinesia-market-in-the-7mm-projected-for-significant-expansion-from-usd-101-million-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Ciliary Dyskinesia Market in the 7MM Projected for Significant Expansion from USD 101 Million| DelveInsight here
News-ID: 3983835 • Views: …
More Releases from ABNewswire
JMR Lawyers Expands Professional Legal Support Services on Brisbane's Southside
Family law expertise in Springwood, QLD matters and choosing the right legal team can transform a stressful situation into a clear, confident journey toward resolution.
Navigating separation, custody, estates, or financial planning isn't just about paperwork. It's about having a trusted partner on your side every step of the way.
Why Local Legal Support Makes a Difference
When you engage Family law expertise in Springwood, QLD [https://jmrlawyers.com.au/understanding-family-law-brisbane-southside-legal-support-makes-difference/], you're not just working with lawyers,…
NameCheap Announces Guide to Choosing the Right SSL Certificate: EV, OV, or DV
It is easy to get lost with the selection of the appropriate SSL certificate. It has various types, each has a different degree of validation and trust. These are the three primary types, DV, OV, and EV SSL certificates. Although all of them secure websites, they are not identical. All types are appropriate to various purposes based on the size of your web site, objectives, and target audience. Knowing the…
Enleaf Founder Adam Chronister to Speak at Committed Mastermind Q4 Event in Nash …
Image: https://www.abnewswire.com/upload/2025/09/80d2799176a64b9e43f5f98584e11b37.jpg
NASHVILLE, Tenn. - Sep 30, 2025 - Adam Chronister, founder and CEO of Enleaf, will serve as a featured speaker at the Committed Mastermind Q4 Event [https://mastermind.committedmastermind.com/], Oct. 23-24, 2025, at the Bridgestone Arena in Nashville, Tenn.
The two-day event brings together entrepreneurs, marketing professionals and business leaders for workshops and sessions on breakthrough growth strategies.
Chronister, recently named one of MSN's "Top 10 Disruptive Entrepreneurs to Watch [https://www.msn.com/en-us/money/smallbusiness/top-10-disruptive-entrepreneurs-to-watch-in-2025/ar-AA1KgGU6]," will share…
New AI Automation Company Brings Corporate-Level Standards to Small Business Gro …
EasyScalers Applies Enterprise Discipline to Help Companies Scale Revenue and Improve Profitability
Delaware, USA - September 30, 2025 - EasyScalers has launched to help B2B businesses access enterprise-quality automation systems traditionally reserved for large corporations. Founded by Singaporean entrepreneur Xavier Tai, who spent 15 years delivering projects for global brands including Disney and Sony PlayStation, EasyScalers brings corporate-level process discipline to AI automation solutions designed for growing businesses.
Image: https://www.abnewswire.com/upload/2025/09/eabd7c04a1b09984af1ec4bd09e6dda8.jpg
The Problem
While Fortune…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
